Yasho Industries Ltd

- There is no immediate plan for new capex or fundraising, as the next phase of capex is not currently on the table. - Management will consider the appropriate course of action, including equity raise, only after achieving 70% utilization of current capacity, expected around Q1 FY26. - Debt repayment will start from April 2025, with INR 25-30 crores planned for FY26. - Currently, the company holds INR 580 crores of debt, of which INR 330 crores is long-term, and debt repayment will focus on this portion. - The company aims to reduce its debt-to-EBITDA ratio from about 5x to closer to 3x by FY26 but did not commit firmly on reaching 2-2.5x soon. - Any decision on raising equity for future expansion will be taken appropriately when the next capex plan is finalized.

- Current Phase 1 capex was INR 600 crores, with INR 400 crores spent on utilities and infrastructure. - Future capacity expansion expected to require approximately INR 200-250 crores, primarily for additional machinery and possibly a small building. - Company planning next capacity ramp-up only after achieving 70% utilization at current assets, currently expected after some delay. - No immediate plans for next capex phase; decision on funding (equity/debt) will be taken closer to that time. - Next capex phase not on the table currently; expected around Q1 FY'26 after utilization targets are met. - Infrastructure and admin facilities have been created to support future capacity needs, minimizing incremental capex for expansion.

- Volume growth target is strong, with an expected 30%-40% increase in industrial chemical volumes to meet sales goals. - Sales volume increased 16-18% YoY recently, with volume growth offsetting price declines. - Revenue growth for FY25 will be challenging due to continued downward pricing pressure despite volume expansion. - Full-year revenue target of INR 900 crores for FY25 is unlikely; clarification on revised target expected in January 2025. - For FY26, revenue target remains INR 1250 crores, considered achievable. - Pakhajan facility utilization expected to rise from 15% in Q2 to 60% by Q4 FY25 and 90% by FY26, driving capacity expansion. - Incremental capacity addition capex estimated around INR 200-250 crores, with subsequent expansions expected at lower capex costs. - US subsidiary launch in January 2025 aims to boost US market reach and sales. - Industrial segment expected to drive major growth over next 3-5 years.

- Volume growth is expected to be strong, particularly driven by the industrial chemicals segment with projections of 30%-40% volume growth to meet sales targets (Page 11). - EBITDA margins are guided to remain in the range of 17%-19%, with optimism to exceed 19% if market conditions allow, supported by improved product mix and ramp-up of Pakhajan facility (Pages 3-4). - Gross margin faced downward price pressures but improved due to product mix; sustainable gross margin targeted around 40% (Pages 7-8). - Pakhajan facility utilization expected to ramp up from 15% to 60% by Q4 FY25, positively impacting margins and fixed cost absorption (Page 4). - Export market growth, especially in mature markets like the USA and Europe, is anticipated to sustain growth, with the new US distribution hub operational from January 2025 to boost reach (Pages 11-14). - Capex plans include smaller incremental spend (~INR200 crores) for capacity expansion post 70% utilization, with ROCE expected to be high on incremental capex (Pages 13-14).

- The company has increased inventory levels at the Pakhajan facility to provide trial material to various customers indicating confirmed orders in hand. - There is some delay in customer approvals for the new plant, causing slower capacity utilization ramp-up. - Management expects Pakhajan facility utilization to reach 60% by end of FY25, with high probability. - Some customer approvals are still pending, especially final customer approvals affecting order finalization. - Export demand is growing robustly, especially in the industrial segment, which is driving order intake. - Management remains confident in long-term customer engagements despite short-term order and market fluctuations. - A US subsidiary will start commercial transactions from January 2025 to improve order reach in the American market. - No specific quantified orderbook value disclosed in the call.